Vanda Pharmaceuticals | VNDA - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 172.31M 174K 2026-09
Agios Pharmaceuticals USD 59.6M 264K 2026-06
Akebia Therapeutics USD 265.42M 199K 2025-12
Alnylam Pharmaceuticals USD 133.88M 141K 2026-09
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 141.14M 564K 2026-06
AstraZeneca USD 1.55B 28K 2026-09
Bristol-Myers Squibb USD 2.04B 7M 2026-06
Eli Lilly USD 943.5M 3.33M 2026-03
Enanta Pharmaceuticals USD 212K 1000 2023-12
Halozyme Therapeutics USD 113.94M 106K 2026-09
Heron Therapeutics USD 188.31M 4.99M 2025-12
Insmed USD 218.28M 1.76M 2026-06
J&J USD 2.41B 1.64M 2026-06
Lexicon Pharmaceuticals USD 363.47M 67K 2025-12
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
Merck USD 2.47B 1.05M 2026-06
Minerva Neurosciences USD 1000 0 2024-09
Moderna USD 391M 2M 2025-09
Novartis USD 1.89B 19.47M 2026-09
Pfizer USD 5.7B 0 2026-06
PTC Therapeutics USD 83.33M 445K 2026-06
Puma Biotechnology USD 5K 0 2024-06
Sanofi EUR 1.2B 0 2026-09
Takeda JPY 1.58B 460K 2026-06
Teva Pharmaceutical Industries USD 1.17B 2M 2026-09
Ultragenyx Pharmaceutical USD 98.6M 300K 2026-06
Vanda Pharmaceuticals USD 58K 0 2024-12
Veracyte USD 80.39M 598K 2026-09